These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24183729)

  • 1. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
    Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
    Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
    Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
    Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
    Russell MR; Liu Q; Fatatis A
    Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
    Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
    Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
    Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
    Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
    Shah GD; Loizos N; Youssoufian H; Schwartz JD; Rowinsky EK
    Cancer; 2010 Feb; 116(4 Suppl):1018-26. PubMed ID: 20127943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
    Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
    EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
    Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
    Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
    Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
    Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 11. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
    Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
    J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
    Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
    Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
    PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
    Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
    J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM; Trinh VA; Posey K; Somaiah N
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
    Bottsford-Miller J; Choi HJ; Dalton HJ; Stone RL; Cho MS; Haemmerle M; Nick AM; Pradeep S; Zand B; Previs RA; Pecot CV; Crane EK; Hu W; Lutgendorf SK; Afshar-Kharghan V; Sood AK
    Clin Cancer Res; 2015 Feb; 21(3):602-10. PubMed ID: 25473001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.